Clinical Trials Logo

Toxicity, Drug clinical trials

View clinical trials related to Toxicity, Drug.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03638375 Active, not recruiting - Adverse Drug Event Clinical Trials

TIL and Anti-PD1 in Metastatic Melanoma

ACTME
Start date: July 31, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The ACTME study is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma. The trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL. The treatment with IFN-alpha will be added after the combination of TIL and nivolumab has proven to be safe.